SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT01953432

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Pharmacogenetic Trial of Noradrenergic Medication for Treatment of Cocaine Abuse

Cocaine use disorders affect approximately 1.5 million Americans annually. Currently, there are no US Food and Drug Administration approved medications for treatment of cocaine dependence; however, both animal and human studies suggest that medications affecting the noradrenergic system can reduce cocaine craving and use. The investigators will study the effect of doxazosin, an alpha-1 adrenergic antagonist, in reducing cocaine use and anxiety symptoms among cocaine-dependent individuals. In addition, the investigators will identify genetic subpopulations of participants who preferentially respond to the medication.

NCT01953432 Cocaine Dependence
MeSH: Cocaine-Related Disorders

2 Interventions

Name: Doxazosin

Description: Doxazosin is initiated at 2 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 4 weeks. Participants will be maintained on 8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.

Type: Drug

Doxazosin

Name: Placebo

Description: Matched placebo daily dosing

Type: Drug

Placebo


Primary Outcomes

Description: Reduction in cocaine use and abstinence rates as assessed by thrice-weekly urine drug screen and self-report

Measure: Reduction in cocaine use

Time: Up to 13 weeks, or for the duration of the participant's involvement in the study

Secondary Outcomes

Description: Weeks in treatment

Measure: Treatment Retention

Time: Up to 13 weeks, or for the duration of the participant's involvement in the study

Description: Reported medication side effects (medication tolerability)

Measure: Adverse events

Time: Up to 13 weeks, or for the duration of the participant's involvement in the study

Description: Self-report of level of craving using visual analog scale (VAS)

Measure: Changes in cocaine craving

Time: Up to 13 weeks, or for the duration of the participant's involvement in the study

Purpose: Treatment

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 R492C

Additionally, this study will identify genetic subpopulations of participants for whom doxazosin is preferentially effective, specifically examining the R492C functional polymorphism of the ADRA1A gene. --- R492C ---



HPO Nodes